Wrote about potential short squeeze yesterday ($GCTK), heres another one
$BYON reported $140.4 million in cash and $34.2 million in debt. This results in a net cash position of approximately $106 million (As of 9/30/2024).
But their other assets is where this gets interesting:
BYON has 7.4 million shares short, 16.3% of shares outstanding and 2.7 days to cover. This kind of short interest can be a catalyst for a potential short squeeze.
Also, recently CEO talked about using tZERO for digital distributions.
Buckle up? $BYON
Wrote about potential short squeeze yesterday ($GCTK), heres another one
$BYON reported $140.4 million in cash and $34.2 million in debt. This results in a net cash position of approximately $106 million (As of 9/30/2024).
But their other assets is where this gets interesting:
This valuation discrepancy suggests that company's core operations are basically being valued at less than zero. Based on this analysis, the fair value of $BYON should likely be several multiples of its current market cap.
$GCTK has an upcoming presentation at the TechBio Showcase on January 14. This could be a catalyst for them, especially if they successful trial outcomes and secure FDA approval.
By eliminating the need for frequent finger pricks and bulky sensors, this thing offers way better solution and user experience than whats currently on the market.
Global demand is big, diabetes tech is an $18 billion industry, projected to grow to $52B by 2029 worldwide.